<DOC>
	<DOCNO>NCT00618969</DOCNO>
	<brief_summary>The purpose study transplant haploidentical related peripheral blood stem cell ( PBSCs ) come relative parent , sibling , child relative half-matched tissue type recipient ( rather completely match ) follow administration reduced-intensity regimen busulfan , melphalan alemtuzumab .</brief_summary>
	<brief_title>Peripheral Blood Stem Cell Transplantation ( PBSCT ) From Haploidentical Related Donors</brief_title>
	<detailed_description>Fewer 35 % patient might benefit allogeneic HCT HLA-identical sib . Transplantation peripheral blood stem cell ( PBSCs ) bone marrow ( BM ) HLA-matched one-locus mismatch unrelated volunteer donor may alternative patient lack HLA-matched sib donor . Despite increase number volunteer unrelated donor national international registry , identification suitable unrelated donor match recipient HLA-A , -B , -C -DRB1 locus ( 8/8 HLA match ) mismatch one locus ( 7/8 HLA match ) still challenge , especially patient African-American multiracial . Additionally , 3- 4-month delay initiation unrelated donor search HCT unacceptably long patient aggressive hematologic malignancy likely relapse progress interval . Transplantation single dual unrelated umbilical cord blood cell ( UCB ) unit another alternative , although problem inadequate cell dos , delay engraftment , graft rejection infection persist adult recipient unrelated UCB transplant . This phase II single-arm open-label study evaluate efficacy safety haploidentical related allogeneic PBSCT use nonmyeloablative preparative regimen intravenous busulfan ( Busulfex® ) , intravenous melphalan ( Alkeran® ) intravenous alemtuzumab ( Campath® ) subject candidate relate unrelated allogeneic hematopoietic cell transplantation ( HCT ; transplantation bone marrow PBSCs ) lack histocompatible relate unrelated donor . This study also evaluate immunological reconstitution follow haploidentical PBSCT measurement circulate T cell receptor excision circle ( TREC ) -positive cell , indicator thymic output . Systematic analysis TREC-positive cell perform recipient haploidentical PBSCT preparative regimen describe protocol .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Age 18 year 75 year . one diagnose : acute myeloid leukemia remission relapse , acute lymphocytic leukemia remission relapse , chronic myeloid leukemia , chronic lymphocytic leukemia , Hodgkin 's disease nonHodgkin 's lymphoma , multiple myeloma , myelodysplastic syndrome , severe aplastic anemia , paroxysmal nocturnal hemoglobinuria . Subjects hematologic malignancy must receive least one previous course chemotherapy biological therapy ( i.e. , subject enrol study initial treatment malignancy ) . Absence healthy relate unrelated volunteer allogeneic donor subject either completely HLA match HLAA , B , C DRB1 ( 8/8 HLA match ) mismatch one HLA locus ( 7/8 HLA match ) . Availability healthy haploidentical relative ( parent , sib child ) able donate peripheral blood stem cell apheresis . Eligibility another clinical therapeutic protocol standardofcare treatment offer high probability cure longterm control subject 's malignancy . Availability relate unrelated 7/8 8/8 HLAmatched allogeneic donor . Severe organ dysfunction Untreated progressive central nervous system involvement malignancy . Subject pregnant breast feeding . Karnofsky score 50 . Seropositivity human immunodeficiency virus ( HIV ) . Life expectancy le 12 week conventional treatment . For subject fertile , refusal practice contraception upon enter study least 12 month PBSCT cessation posttransplant immunosuppressive treatment , whichever occurs later .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Haploidentical</keyword>
	<keyword>peripheral blood stem cell transplantation</keyword>
	<keyword>leukemia</keyword>
	<keyword>myeloma</keyword>
	<keyword>Hodgkin 's disease</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
</DOC>